Cancer Drugs Fund in England, United Kingdom of Great Britain and Northern Ireland, 2016-2024
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
World Health Organization
Abstract
Description
3 p.
The Cancer Drugs Fund in England, United Kingdom of Great Britain and Northern Ireland, 2016–2024 policy report documents the rationale, design, implementation and reported outcomes of the reformed Cancer Drugs Fund (CDF), which has operated since 2016 as a managed access mechanism for cancer medicines within the National Health Service in England. The publication describes how the policy was introduced in response to concerns regarding the financial sustainability, efficiency and transparency of the previous CDF model. Under the reformed approach, cancer medicines that show potential for cost-effectiveness but remain subject to significant clinical uncertainty may receive temporary funding while additional evidence is collected to inform subsequent appraisal by the National Institute for Health and Care Excellence (NICE). The report outlines the eligibility criteria, funding arrangements, managed access agreements and governance processes that support the operation of the scheme. The report reviews implementation and outcomes between 2016 and 2024, including the number of managed access agreements established, medicines and indications covered, patient access to treatment, expenditure trends and reassessments conducted by NICE. It also examines remaining challenges related to uncertainty reduction through evidence generation and discusses the influence of the CDF model on similar funding mechanisms adopted elsewhere in the United Kingdom. The publication contributes to WHO’s Pharmaceutical Pricing Policy Report Series by providing a structured description of a policy approach intended to balance timely access to innovative cancer treatments with value for money and evidence-informed decision-making
The Cancer Drugs Fund in England, United Kingdom of Great Britain and Northern Ireland, 2016–2024 policy report documents the rationale, design, implementation and reported outcomes of the reformed Cancer Drugs Fund (CDF), which has operated since 2016 as a managed access mechanism for cancer medicines within the National Health Service in England. The publication describes how the policy was introduced in response to concerns regarding the financial sustainability, efficiency and transparency of the previous CDF model. Under the reformed approach, cancer medicines that show potential for cost-effectiveness but remain subject to significant clinical uncertainty may receive temporary funding while additional evidence is collected to inform subsequent appraisal by the National Institute for Health and Care Excellence (NICE). The report outlines the eligibility criteria, funding arrangements, managed access agreements and governance processes that support the operation of the scheme. The report reviews implementation and outcomes between 2016 and 2024, including the number of managed access agreements established, medicines and indications covered, patient access to treatment, expenditure trends and reassessments conducted by NICE. It also examines remaining challenges related to uncertainty reduction through evidence generation and discusses the influence of the CDF model on similar funding mechanisms adopted elsewhere in the United Kingdom. The publication contributes to WHO’s Pharmaceutical Pricing Policy Report Series by providing a structured description of a policy approach intended to balance timely access to innovative cancer treatments with value for money and evidence-informed decision-making